Results 51 to 60 of about 144,610 (311)

Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer

, 2015
Purpose: There is a need to identify more sensitive clinico-pathological criteria to assess the response to Neo-ACT and guide subsequent adjuvant-therapy.
Ball, G., Palmer, D., Pinder, S., MacMilan, RD, Moseley, Paul M., MacMilan, R. D., Pinder, Sarah; id_orcid, Latham, B, Ellis, I., Cornford, Eleanor, Ball, G, Price, James, Moseley, PM, Lee, A. H. S., Ball, Graham, Chan, A, Chan, SYT, Chan, S. Y. T., Abdel-Fatah, TM, Palmer, David, Latham, Bruce, Silverman, R, Moseley, P. M., Chan, Arlene, Palmer, D, Cornford, E, MacMilan, R., Price, J., Chan, A., Cornford, E., Ellis, IO, Abdel-Fatah, Tarek M., Lee, AHS, Ellis, I. O., Pinder, S, Moseley, P., Latham, B., Abdel-Fatah, T. M., Silverman, Rafael, Lee, A., Lee, Andrew H S, MacMilan, R. Douglas, Ellis, Ian O., Chan, Stephen Y T, Silverman, R., Abdel-Fatah, T., Chan, S., Price, J   +47 more
core   +1 more source

Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review

, 2021
Despite advances in adjuvant immuno- and targeted therapies, the risk of relapse for stage III melanoma remains high. With 43 active entries on clinicaltrials.gov (8 July 2020), there is a surge of interest in the role of contemporary therapies in the ...
Ashley Yu, Alexandre Tran, Risa Shorr, Kerianne Boulva, Carolyn Nessim, Xinni Song, Sameer Apte, Michael Ong   +7 more
core   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

Preoperative Management of Locally Advanced Rectal Cancer and the Role of Restaging MRI: An Australasian Perspective

World Journal of Colorectal Surgery, 2020
Background: Major advances in the management of locally advanced rectal cancer has led to controversies and varying clinical practices among colorectal surgeons, such as patient selection for neoadjuvant therapy and preferred regimen for neoadjuvant ...
Milton Mui, Joseph C. Kong, Glen R. Guerra, Alexander G. Heriot   +3 more
doaj   +1 more source

Perioperative chemotherapy in colorectal cancer with peritoneal metastases: A global propensity score matched studyResearch in context

EClinicalMedicine, 2023
Summary: Background: There is a paucity of studies evaluating perioperative systemic chemotherapy in conjunction with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colorectal cancer peritoneal ...
Peter H. Cashin, Jesus Esquivel, Stein G. Larsen, Winston Liauw, Nayef A. Alzahrani, David L. Morris, Vahan Kepenekian, Isabelle Sourrouille, Frédéric Dumont, Jean-Jacques Tuech, Cécilia Ceribelli, Beranger Doussot, Olivia Sgarbura, Francois Quenet, Olivier Glehen, Oliver M. Fisher   +15 more
doaj   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Administered neoadjuvant and adjuvant therapy regimens.

, 2022
All regimens, both neoadjuvant and adjuvant therapy, with the number of cycles used for both patients treated with neoadjuvant therapy and upfront surgery. NAT = Neoadjuvant therapy, US = Upfront surgery. (DOCX)
Harri Mustonen (641410), Hanna Seppänen (751179), Jaana Hagström (476954), Anna Maria Nurmi (12524924), Caj Haglund (476956)   +4 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate.

PLoS ONE, 2019
OBJECTIVES:Complete resection of thymic neoplasms is important for achieving a favorable prognosis; however, the efficacy of neoadjuvant therapy remains controversial.
Jee Won Suh, Seong Yong Park, Chang Young Lee, Seung Hwan Song, Dae Joon Kim, Hyo Chae Paik, Kyoung Young Chung, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho, Jin Gu Lee   +10 more
doaj   +1 more source

Neoadjuvant Therapy

Surgical Oncology Clinics of North America
Summary Neoadjuvant therapy (NAT) for early breast cancer was first introduced in the 1980s to downstage large, inoperable tumors, and thereby enable less extensive surgical resections. Beyond its surgical benefits, NAT offers the unique advantage of assessing treatment response in vivo, informing subsequent adjuvant strategies, and ...
Vanessa Castagnaviz, Simon Peter Gampenrieder   +1 more
openaire   +2 more sources